Purpose:To date, the different biopsy methods, such as CT-guided pleural biopsy, mediastinal biopsy, endosonography and thoracoscopy have their limitations in diagnosing pleural malignancies, such as mesothelioma. Sampling errors frequently occur resulting in the common histological finding of ‘non-specific pleuritic/fibrosis’, which presents a great uncertainty for clinicians and patients. Confocal laser endomicroscopy (CLE) provides real-time imaging on a cellular level, however data of CLE in pleural malignancies are lacking.
From the blog
Opdivo, Yervoy, and Keytruda: Immunotherapy Options for Mesothelioma
Immunotherapy treatments are becoming known alternatives to chemotherapy in cancer patients who have had little success with traditional cancer treatments. With mesothelioma, often times first line treatments have little effect because the cancer is typically in the advanced stages by the time it is detected. While there currently is no[…]
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Purpose:The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
Determining and Prolonging Survival Rates In Mesothelioma
The average survival rate for mesothelioma after diagnosis is less than one year; however, certain individuals will survive longer than others, but the reason as to why this is, is largely unknown. The latest study to be published in Histopathology investigates what it is in the body that determines a[…]
Mesothelioma Awareness Day 2017
Mesothelioma Awareness Day, which takes place on Tuesday, September 26, 2017, aims to educate and inform society about the deadly cancer caused by asbestos exposure, and how funding is a critical component in mesothelioma research. Mesothelioma Awareness Day was established in 2004 by the Meso Foundation and eventually became National[…]
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma (MesoRT)
Purpose:This is a monocentric prospective study of radiotherapy using accelerated hypofractionation with Tomotherapy in Malignant Pleural Mesothelioma (MPM) patients after pleurectomy / decortication (P / D) or biopsy. The treatment will be delivered using Tomotherapy, that allows to adopt dose accelerated hypofraction criteria. Treatment duration is 5 consecutive days.
Study: More Mesothelioma Diagnoses Are Discovered At Autopsy Than Clinically
A mesothelioma diagnosis often a grim one; fatality rates are high as there is no known cure. Treatment can help alleviate pain and symptoms, but more often than not, patients will succumb to this deadly asbestos-caused disease. While treatment has proven to be difficult, diagnosing mesothelioma and other asbestos-caused illnesses[…]
Trimodality Therapy Increases Survival; Immunotherapy Treatment Approved by FDA
Since mesothelioma is often difficult to treat, scientists and researchers look to combination treatments and therapies to improve chances of patients’ survival. There is no “one” treatment that is used across the board in treating mesothelioma, because patients react differently, whether it is to chemotherapy, radiation therapy, immunotherapy, or surgery.[…]
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Purpose:The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
Mesothelioma Treatments Used Alongside Surgery – A Clinical Trial
Rare and aggressive in nature, mesothelioma is often a fatal cancer mainly due to its lack of response to most treatments. Surgical options have a higher chance of success for those in the early stages of the disease, but since there is a long latency period between asbestos exposure and[…]
Skip to content